Flibanserin CAS 167933-07-5 API Active Pharmaceutical Ingredient

Product Description:

Product Name: Flibanserin CAS NO: 167933-07-5          

Synonyms:

1,3-Dihydro-1-(2-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)ethyl)-2H-benzimidazol-2-one;

1-(2-(4-(3-Trifluoromethylphenyl)piperazin-1-yl)ethyl)benzimidazol(1H)-2-one;

3-[2-[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one;

Chemical & Physical Properties:

Appearance: White powder

Assay :≥99.0%

Density: 1.292 g/cm3

Refractive Index: 1.566

Storage Temp.: 2-8℃

Solubility: DMSO: soluble10mg/mL, clear

Safety Information:

Symbol: GHS06

Hazard Declaration: H301; H315; H319; H335

Caution Statements: P261; P301 + P310; P305 + P351 + P338

Signal Word: Danger

Flibanserin, sold under the trade name Addyi, is a medication approved for the treatment of pre-menopausal women with hypoactive sexua/l desire disorder (HSDD). The medication increases the number of satisfying sexua/l events per month by about one half over placebo from a starting point of about two to three. The certainty of the estimate is low. The side effects of dizziness, sleepiness, and nausea occur about three to four times more often.

Development by Boehringer Ingelheim was halted in October 2010 following a negative evaluation by the U.S. Food and Drug Administration. The rights to the drug were then transferred to Sprout Pharmaceuticals, which achieved approval of the drug by the US FDA in August 2015.

HSDD was recognized as a distinct sexua/l function disorder for more than 30 years, but was removed from the Diagnostic and Statistical Manual of Mental Disorders in 2013, and replaced with a new diagnosis called female sexua/l interest/arousal disorder (FSIAD).

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.